A Phase 1 Dose-Escalation Study To Evaluate The Safety And Pharmacokinetics Of Palifermin In Pediatric Subjects With Acute Leukemias Undergoing Myeloablative Therapy And Allogeneic Hematopoietic Stem Cell Transplant
Year: 2010
Type: article
Study design: Clinical Trial
Abstract: Palifermin at 60ug/kg/dose, decreases the severity of oral mucositis (OM) in adults with hematologic malignancies undergoing SCT. Currently there is no proven therapy to decrease severe OM in pediatric subjects receiving chemotherapy +/- radiation for SCT. Reducing severe OM in pediatrics should decrease infection, pain, and enteral nutrition use and improve outcome following SCT.
Authors: J. Morris, S. Neudorf, T. Moore, A. Shah, M. Graham, V. Aquino, R. Duerst, M. Neidler, M. deChateau, D. Berger, C. Morris
Institutions: Loma Linda University Medical Center, Children's Hospital of Orange County, University of California, Los Angeles, Mattel Children's Hospital, Children's Hospital Los Angeles, The University of Texas Southwestern Medical Center, Lurie Children's Hospital, Swedish Orphan Biovitrum (Sweden), Amgen (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2081312065